FDA Considers Parsaclisib for Approval in FL, MZL, and MCL
November 1st 2021The FDA is considering an application parsaclisib as treatment of patients with relapsed or refractory follicular lymphoma, marginal zone lymphoma, and mantle cell lymphoma, and granted priority review for 2 of the 3 indications.
Read More
New Option After Tisagenlecleucel for Patients With R/R LBCL Now in Development
October 20th 2021Following treatment with chimeric antigen receptor T-cell therapy, patients with relapsed or refractory large B-cell lymphoma require more options. Investigators are now evaluating an interleukin-17 agent.
Read More
Improving Risk/Benefit of Frontline Classical Hodgkin Lymphoma Treatment
October 17th 2021Many options exist for advanced stage cHL, with varying degrees of toxicity. Ranjana H. Advani, MD, gives an overview of each during a presentation at the NCCN 2021 Virtual Congress: Hematologic Malignancies.
Read More
Survival Data is a Forefront Consideration in Choosing Third-Line DLBCL Treatment
October 2nd 2021In an interview with Targeted Oncology, Patrick Connor Johnson, MD, discussed the top considerations taken into account by physicians when choosing a third-line therapy for diffuse large B-cell lymphoma.
Read More
Lasting Effects of Lymphoma Treatments
September 27th 2021Ingrid Glimelius, MD, PhD, a senior lecturer and assistant professor in the Department of Immunology, Genetics and Pathology, Experimental and Clinical Oncology at Uppsala Universitet, discusses the lasting effects of lymphoma treatments.
Watch